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Abstract
Background: This study compared the combination of estimated glomerular filtration rate (eGFR) and urine
albumin-to-creatinine ratio (UACR) vs. eGFR and urine protein reagent strip testing to determine chronic kidney
disease (CKD) prevalence, and each method’s ability to predict the risk for cardiovascular events in the general
Japanese population.
Methods: Baseline data including eGFR, UACR, and urine dipstick tests were obtained from the general population
(n = 22 975). Dipstick test results (negative, trace, positive) were allocated to three levels of UACR (<30, 30–300, >300),
respectively. In accordance with Kidney Disease Improving Global Outcomes CKD prognosis heat mapping, the cohort
was classified into four risk grades (green: grade 1; yellow: grade 2; orange: grade 3, red: grade 4) based on baseline
eGFR and UACR levels or dipstick tests.
Results: During the mean follow-up period of 5.6 years, 708 new onset cardiovascular events were recorded. For CKD
identified by eGFR and dipstick testing (dipstick test≥ trace and eGFR <60 mL/min/1.73 m2), the incidence of CKD was
found to be 9 % in the general population. In comparison to non-CKD (grade 1), although cardiovascular risk was
significantly higher in risk grades ≥3 (relative risk (RR) = 1.70; 95 % CI: 1.28–2.26), risk predictive ability was not
significant in risk grade 2 (RR = 1.20; 95 % CI: 0.95–1.52). When CKD was defined by eGFR and UACR (UACR ≥30 mg/g
Cr and eGFR <60 mL/min/1.73 m2), prevalence was found to be 29 %. Predictive ability in risk grade 2 (RR = 1.41; 95 %
CI: 1.19–1.66) and risk grade ≥3 (RR = 1.76; 95 % CI: 1.37–2.28) were both significantly greater than for non-CKD.
Reclassification analysis showed a significant improvement in risk predictive abilities when CKD risk grading was based
on UACR rather than on dipstick testing in this population (p < 0.001).
Conclusions: Although prevalence of CKD was higher when detected by UACR rather than urine dipstick testing, the
predictive ability for cardiovascular events from UACR-based risk grading was superior to that of dipstick-based risk
grading in the general population.
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Background
Since the National Kidney Foundation began drawing at-
tention to chronic kidney disease (CKD), several studies
have reported that CKD is an independent risk factor for
cardiovascular disease and cardiovascular mortality [1, 2].
For people with CKD, the risk for death from a cardio-
vascular event is up to 20 times greater than the risk for
requiring dialysis or transplantation [3]. A recent meta-
analysis obtained from 1.5 million inhabitants in mainly
Western populations reported that albuminuria levels are
important for evaluating overall risk for CKD independent
of estimated glomerular filtration rate (eGFR) [4]. In
accordance with Kidney Disease Improving Global Out-
comes (KDIGO) recommendations, several clinical practice
guidelines in Europe, Australia, and Japan have recom-
mended that prognostic grading for CKD should be based
on a combination of urine albumin levels and eGFR [5–7].
Measurement of urine albumin, however, is not easily
performed in clinical and screening settings, as it is ex-
pensive, creates a delay in the availability of results, and
must be performed by laboratory technicians. Accord-
ingly, despite relatively limited evidence for its clinical
utility, urine dipstick testing remains a popular tool in
epidemiological surveys.
To date, few reports have described the relationship
between urine albumin-to-creatinine ratio (UACR) and
urine protein reagent strip testing in terms of utility for
CKD definition and risk grading in the general popula-
tion. Specifically, it is not yet known how much the
characteristics, prevalence, and risk predictive abilities
for cardiovascular events of CKD change when UACR is
used rather than dipstick testing for detection of this
condition. In the current study, we examined the value
of using UACR rather than urine dipstick testing to de-
termine CKD prevalence, and compared each method’s




This study was a prospective community-based cohort
study examining cardiovascular events in Iwate Prefec-
ture in northern Honshu, Japan. A total of 26 469 resi-
dents in Ninohe, Kuji, and Miyako consented to
participate in the study. All participants provided written
informed consent. The study was part of the Iwate-
KENCO (Kenpoku Cohort) study, as described previ-
ously [8–10].
The baseline survey was conducted between 2002 and
2004 and comprised a self-administered lifestyle ques-
tionnaire, blood pressure measurements, anthropometri-
cal measurements, blood collection, and random spot
urine sampling. A total of 22 975 participants were en-
rolled who had complete data for eGFR, UACR, and
dipstick urinalysis for proteinuria with no past history of
stroke or myocardial infarction (7 841 men and 15 134
women, aged 40–89 years, mean age of 62.9 years).
The study protocol was approved by the Ethics Com-
mittee of Iwate Medical University and conducted in ac-
cordance with the principles contained in the Declaration
of Helsinki.
Blood pressure was measured twice using a Nippon
Colin BP-103i II blood pressure monitor (model 513000;
Nippon Colin, Komaki, Japan), with the mean value be-
ing used for statistical analysis. Peripheral venous blood
samples were taken from the upper arm with partici-
pants in a seated position after at least 5 min rest. Blood
samples were centrifuged immediately after collection
and used for measurements. Creatinine (Cr) concentra-
tions in urine and serum were measured by the enzym-
atic method using a Hitachi 7700 automatic analyzer
with standardized calibrators (Hitachi, Tokyo, Japan),
and urine albumin measurement was by immunonephe-
lometry (N-antiserum to human albumin assay; Dade
Behring, Tokyo, Japan). Urine albumin concentrations
were corrected to urine Cr concentrations and expressed
as UACR mg/g Cr. Urine protein levels were semi-
quantified using a Hema Combistix urine protein re-
agent testing strip (Siemens Healthcare Diagnostics,
Tokyo, Japan). Results of the urine dipstick test were
visually interpreted by trained laboratory technicians
and recorded as (−), trace, (1+), (2+), or (3+). Data from
women who said they were menstruating were excluded
in the study, as the urine test might be affected by
hemoglobin in urine. eGFR was calculated using the for-
mula devised by the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) [11].
Following practice guidelines developed by the KDIGO
proposal [12], participants were divided into an 18-part
matrix comprising six categories of eGFR (≥90, 60–89,
45–59, 30–44, 15–29, <15 mL/min/1.73 m2) across three
categories of UACR (<30, 30–300, >300) or dipstick test
(negative, trace, positive) as shown in Fig. 1. The reliability
of the allocation of dipstick urinalysis (negative, trace,
positive) to three levels of UACR (<30, 30–300, >300) has
been reported in previous studies [13, 14]. Accordingly,
Fig. 1 Modified KDIGO risk grading for CKD (six rows × three
columns = 18 matrix)
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the definition of CKD was two ways (the dipstick-based
definition = dipstick test ≥ trace and eGFR <60 mL/min/
1.73 m2: the UACR-based definition = UACR ≥30 mg/g Cr
and eGFR <60 mL/min/1.73 m2) Participants were then
classified into four risk grades based on the matrix as
shown in the heat map for both definitions (Fig. 1) (green:
non-CKD (grade 1); yellow: moderately increased risk
(grade 2); orange: high risk (grade 3); red: very high risk
(grade 4)).
Diabetes mellitus was defined as a hemoglobin A1c
(HbA1c) level ≥6.5 %, fasting blood glucose level
≥126 mg/dL, blood glucose ≥200 mg/dL, or undergoing
treatment with antidiabetic drugs including insulin.
Hypertension was defined as systolic blood pressure
≥140 mmHg, diastolic blood pressure ≥90 mmHg, or
undergoing treatment with antihypertensive drugs. Hyper-
lipidemia was defined as total cholesterol ≥240 mmHg or
undergoing treatment with antihyperlipidemic drugs.
Obesity was defined as body mass index (BMI) ≥25.
Endpoint
The endpoint was determined as the composite of car-
diovascular events (stroke, myocardial infarction, and
sudden cardiac death occurring within 24 h of the onset
of acute symptoms and signs). The incidence of hospital-
ized myocardial infarction was registered according to
criteria of the MONICA study [15]. The study team vis-
ited all referral hospitals within the study area and
reviewed medical charts or discharge summaries of al-
most all admitted patients. In cases where clinical data
met the definition, the patient’s data were registered.
Stroke events were identified by accessing the Iwate Pre-
fecture stroke registration program, which included the
entire area where participants lived; details have been
described previously [16, 17]. The follow-up survey for
acute myocardial infarction and stroke was carried out
from the date of the baseline survey until March 2009.
The research methods have been described in detail pre-
viously [8–10, 17].
Statistical analysis
Continuous variables are expressed as mean ± SD. Com-
parisons among CKD risk grades were conducted using
one way analysis of variance or chi-squared tests. The
Cox proportional hazards model was used to analyze the
relative risk (RR) for cardiovascular events in each risk
grade adjusted by several cofounding factors (age, sex,
hypertension, hyperlipidemia, diabetes mellitus, current
smoking, BMI, and atrial fibrillation). To determine con-
cordance between two types of urine protein levels on a
dichotomous outcome of UACR (<30, 30–300, >300)
and the urine dipstick test (negative, trace, positive), the
kappa statistic was calculated. Analyses were performed
using the SPSS 20.0 for Windows. Testing the utility of
CKD risk grading employing UACR rather than dipstick
testing was performed by reclassification tables and
tested by Net Reclassification Improvement (NRI) and
Integrated Discrimination Improvement (IDI) using the
R 3.0.2 software package (www.r-project.org).
Results
Clinical characteristics and prevalence
Table 1 shows the clinical backgrounds of the study par-
ticipants. The average eGFR value for the entire cohort
was 76.8 mL/min/1.73 m2. Seven hundred and eight par-
ticipants experienced a first onset of a cardiovascular
event during the follow-up period (myocardial infarction
or sudden cardiac death: n = 145; stroke: n = 563).
As shown in Fig. 2 (left), the dipstick-based definition
of CKD (dipstick test ≥ trace and eGFR <60 mL/min/
1.73 m2) showed the prevalence of CKD in the general
population as 9 % (men 12 %, women 7 %) and preva-
lence rates of 91 % for risk grade 1 (green), 6 % for grade
2 (yellow), 2 % for grade 3 (orange), and 1 % for grade 4
(red). As shown in Fig. 2 (right), the UACR-based defin-
ition (UACR ≥30 mg/g Cr and eGFR <60 mL/min/
1.73 m2) showed the prevalence of CKD as 29 % in the
general population (men 29 %, women 28 %), with pro-
portions of 71 % in risk grade 1 (green), 25 % in grade 2
(yellow), 3 % in grade 3 (orange), and 1 % in grade 4
(red). The prevalence of CKD according to the UACR-
based definition was nearly three times that of the
dipstick-based definition (9 % compared with 29 %).
For both methods of CKD assessment, age, BMI, and
percentages for diabetes mellitus, hypertension, and atrial
fibrillation rose significantly with increasing progression
of risk grade, but percentages for hyperlipidemia and
current smoking did not differ across risk grades
(Table 1).
For dipstick-based risk grades, 60 % of CKD cases
showed a negative indication for proteinuria. This result
suggests that this method for CKD assessment was
mainly based on decreased eGFR (<60 mL/min/1.73 m2)
with no increase in urine protein levels. In contrast,
79 % of UACR-based CKD cases had elevated UACR
levels (≥30 mg/g Cr) without reduced eGFR.
Relationship between UACR and dipstick testing
To examine the relationship between UACR levels (<30,
30–300, >300) and semi-quantitative dipstick test results
(negative, trace, positive), a multiple comparison graph
was constructed (Fig. 3). Even when dipstick urinalysis
was negative, 22 % of participants had UACR ≥30 mg/g
Cr. When the degree of coincidence between UACR
levels (<30, 30–300, >300) and dipstick results (negative,
trace, positive) was tested using the kappa statistic, the
coefficient was relatively low (0.171). Sensitivity of the
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urine dipstick test (≥ + 1) for UACR (more than 30 mg/g Cr)
was 8 %, and specificity was 100 %.
Risk grades and cardiovascular events
When compared with the non-CKD group (risk grade 1),
RR for cardiovascular events derived from a Cox propor-
tional hazards model was 1.36 (95 % CI: 1.12–1.65) for
dipstick-based CKD, and 1.47 (95 % CI: 1.25–1.72) for
UACR-based CKD. Both methods of CKD assessment
on the whole showed similar predictive abilities for
cardiovascular events. When the cohort was divided
into four risk grades based on urine dipstick testing,
RR for cardiovascular events were 1.20 (95 % CI:
0.95–1.52) for grade 2 and 1.70 (95 % CI: 1.28–2.26)
for grade 3 and above, showing no significant increase
in RR in grade 2 (Fig. 4). On the other hand, for
UACR-based grades, there was a significant increase
in RR for cardiovascular events in both grade 2 (RR:
1.41; 95 % CI: 1.19–1.66) and grade 3 and above (RR:
1.76; 95 % CI: 1.37–2.28).
Reclassification analysis
Risk stratification capacities for cardiovascular events for
dipstick-based risk grades (low risk (grade 1), intermedi-
ate risk (grade 2), high risk (grades 3 and 4)) vs. UACR-
based grades derived from the reclassification table are
shown in Fig. 5. In the events group (n = 708), 80 % were
categorized as low risk by the dipstick-based model,
compared with 51 % by the UACR-based risk grade. In
addition, according to dipstick-based CKD classifica-
tions, prevalence of CKD was only 20 % in the event
group (grade ≥ 2), whereas with UACR-based CKD clas-
sification, prevalence of CKD was 49 %.
Fig. 2 Proportion of CKD risk grades for dipstick- and UACR-based
definitions
Table 1 Baseline characteristics among CKD risk grades in the general population
Total
(n = 22,975)











Grade 3 & 4
(969)
Age(year) 62.9 ± 10.0 62.2 ± 9.8 70.6 ± 8.7 69.7 ± 9.1 < 0.001 61.3 ± 9.8 66.3 ± 9.3 70.6 ± 8.4 < 0.001
Male 34.1 % 32.9 % 45.3 % 49.8 % < 0.001 33.9 % 33.2 % 43.9 % < 0.001
BMI(kg/m
2
) 24.0 ± 3.3 24.0 ± 3.2 24.3 ± 3.4 25.1 ± 3.6 < 0.001 23.8 ± 3.1 24.6 ± 3.5 25.0 ± 3.6 < 0.001
Hypertension 41.5 % 39.4 % 58.1 % 72.7 % < 0.001 34.4 % 59.6 % 72.5 % < 0.001
Diabetes Mellitus 6.6 % 6.1 % 8.9 % 19.0 % < 0.001 4.9 % 9.9 % 16.1 % < 0.001
Dyslipidemia 16.4 % 16.2 % 18.0 % 18.8 % 0.052 15.7 % 17.7 % 20.3 % 0.052
Current Smoking 12.0 % 12.0 % 11.6 % 14.1 % 0.246 12.3 % 11.0 % 12.1 % 0.246
Atrial Fibrillation 1.4 % 1.1 % 3.8 % 5.7 % < 0.001 0.8 % 2.6 % 5.2 % < 0.001
UACb < 30 75.5 % 79.0 % 52.1 % 10.8 % < 0.001 100 % 14.1 % 6.4 % < 0.001
UAC 30-300 22.7 % 20.9 % 42.5 % 39.4 % 0 % 85.9 % 45.2 %
UAC > 300 1.8 % 0.1 % 5.4 % 49.8 % 0 % 0 % 48.4 %
Proteinuria (dip stick)
- Negative (−) 96.4 % 100 % 75.4 % 21.9 % < 0.001 99.8 % 93.7 % 53.7 % < 0.001
- Trace (+/−) 1.8 % 0 24.6 % 9.7 % 0.2 % 4.5 % 14.2 %
- Positive (≥ +) 1.8 % 0 0 68.4 % 0 1.8 % 32.1 %
eGFR(mL/min/1.73m
2
) 76.8 ± 10.1 78.5 ± 7.8 60.3 ± 10.8 58.8 ± 18.9 < 0.001 78.8 ± 7.9 74.2 ± 10.7 58.7 ± 16.2 < 0.001
Number of the Events
- AMI 145 109 22 15 < 0.001 75 51 20 < 0.001
- Stroke 563 455 65 42 < 0.001 286 215 61 < 0.001
- Composite event 708 564 87 57 < 0.001 361 266 81 < 0.001
a Differences among the CKD grades
b Urine Albumin Creatinine Ratio
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These results suggest that when the UACR level was
used rather than dipstick testing for heat map risk grad-
ing, overall predictive ability for cardiovascular events
significantly improved (NRI = 0.232, p < 0.001; IDI =
0.0024, p < 0.001).
Discussion
Results of this study suggest that the cardiovascular pre-
dictive performance for CKD risk grading based on
UACR plus reduced eGFR (UACR-based risk grading)
was superior to that of dipstick testing plus reduced
eGFR (dipstick-based risk grading) in the general
population.
In addition to generating a high degree of risk for the
development of end-stage renal disease, CKD is also an
important risk factor for cardiovascular events such as
atherosclerotic coronary heart disease, stroke, and all-
cause mortality [1, 2, 4]. CKD is therefore a more im-
portant risk factor for cardiovascular disease than dia-
betes [18]. Several studies have reported that the
number of patients experiencing cardiovascular events
and cardiovascular death is greater than the number re-
ceiving dialysis [1, 3]. It has been determined that the
coexistence of CKD in patients with cardiac disorders is
one of the important independent prognostic markers
[19, 20]. In view of this, it is recommended that patients
at high risk of a cardiovascular event should have the
risk managed early on, and should undergo screening to
determine both GFR and urine albumin [21].
UACR measurement is somewhat costly compared
with dipstick urinalysis, especially in mass screening set-
tings. Therefore, although dipstick testing has low sensi-
tivity for renal dysfunction [22], this form of testing is
frequently used in general population studies because of
its simplicity and low cost. Few studies have reported on
the relationship between UACR and dipstick testing in
large-scale general population samples of more than 20
000 participants. Konta et al. reported that, in the gen-
eral population (n = ~2 300), cases with negative dipstick
test results sometimes showed UACR ≥30 mg/g Cr, and
that even trace levels of proteinuria detected by dipstick
testing often showed UACR ≥300 mg/g Cr in diabetic or
elderly patients [13]. Indeed, the degree of coincidence
between UACR and dipstick testing was suboptimal in
the current study’s population (Fig. 3).
To the best of the authors’ knowledge, no reports have
directly compared the two methodologies (UACR-based
risk grading or dipstick-based risk grading) to determine
the better cardiovascular risk predictor in screening set-
tings for the general population. The current study sug-
gests that risk grading based on UACR is superior for
predicting the development of cardiovascular events
compared with dipstick-based grading (Fig. 5).
Prevalence of UACR >30 mg/g Cr was found to be
25 % in the current study, a rate clearly higher than
those found in populations in North America (NHANES
III: 9 %) [23], Europe (PREVEND study: 7 %) [24], and
Australia (AusDiab Kidney study: 6 %) [25]. The reason
for the high prevalence of significant albuminuria in our
population remains unknown. It may be, however, be-
cause of the higher age of our study cohort, as partici-
pants under 40 years of age were excluded. The cohort
also included a high proportion of women (65 %). As
women excrete less Cr per day than men, the urine albu-
min concentration corrected to the urine Cr concentra-
tion may have been calculated to be relatively high, and
therefore easily exceeded the threshold of microalbumi-
nuria of >30 mg/g Cr. It is possible that these factors
contributed to the relatively high prevalence of UACR-
based CKD in women in the current cohort.
Fig. 3 Multiple comparison graph of UACR and dipstick tests
Fig. 4 Relative risks and 95 % CI for cardiovascular events for two
types of CKD risk grades
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Given the high prevalence of microalbuminuria in this
cohort, the high frequency of CKD was mainly because
of the high incidence of UACR ≥30 mg/g Cr. Few re-
ports directly describe the prevalence of CKD using
UACR combined with the modern eGFR calculation
(CKD-EPI) in a large number of participants. Therefore,
the true prevalence of CKD as defined by UACR levels
and reduced eGFR within the general population re-
mains unclear. It seems unlikely that the high prevalence
of CKD would be specific to the current population. Ya-
mamoto et al. reported that 24 % of patients with a
negative dipstick test showed elevated UACR ≥30 mg/g
Cr [26], which is almost the same as the value seen in
the current study (22 %). Terawaki et al. reported that of
the 241 159 participants who received specific health ex-
aminations (mean age: 63 years, 39 % men), mean eGFR
was 76 mL/min/1.73 m2 [27], which again is almost the
same as the current study. It therefore appears unlikely
that renal function in the current cohort differs from
that in populations from other regions of Japan.
Under the Japanese health insurance system, routine
measurement of urine albumin is permitted for patients
at high risk for cardiovascular disorders such as diabetes
mellitus but not for other disorders. Microalbuminuria
has been reported to be a risk factor for cardiovascular
disease among non-diabetic and non-hypertensive pa-
tients [28]. It is possible that for patients with diabetes,
hypertension, and obesity, cardiovascular risk assessment
including albumin measurement for identification of
CKD and more strict management of underlying disor-
ders may improve prognosis. Hence, it may be beneficial
to measure UACR to detect CKD even in populations at
moderate cardiovascular risk, specifically diabetic, hyper-
tensive, and obese people. As urine albumin measure-
ment is relatively expensive compared with the cost of
dipstick testing, further studies are required to identify
the cost effectiveness of CKD screening using UACR for
reducing cardiovascular events and mortality.
The current study has several strengths. To the best of
the authors’ knowledge, this study included the largest
general population sample in whom UACR and urine
dipstick testing has been performed. UACR was mea-
sured in fresh urine samples without long term freezing
and repeated thawing. Cardiovascular events were cap-
tured prospectively according to previously determined
standard epidemiological criteria and confirmed by re-
search staff on medical chart reviews. Baseline data in-
cluding clinical characteristics and biochemical data
were determined well before the start of the follow-up
study. However, despite the study’s merits, some limita-
tions must be considered when interpreting the results.
First, measurement of urine albumin was based on a sin-
gle measurement, which did not completely comply with
the clinical requirement for multiple urine collections
for establishing a diagnosis of CKD. Second, what effects
prescribed drugs such as renin-angiotensin inhibitors
have on cardiovascular events and urine albumin levels
in the current population are not known. Third, the
study employed only the CKD epidemiology collabor-
ation (CKD-EPI) equation for eGFR and did not use
other formulae, since there is no consensus on the best
equation for eGFR in Asian populations.
Fig. 5 Reclassification analysis. Changes in risk stratification capacity derived from reclassification tables in terms of dipstick-based CKD risk grades
vs. UACR-based CKD risk grades. For comparison with the dipstick-based model, the percentage of risk grades 3–4 in the events group increased
(from 20 to 49 %) in the UACR-based model. NRI: Net Reclassification Improvement; IDI: Integrated Discrimination Improvement
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Conclusion
Although the prevalence of CKD in the general popula-
tion was found to be higher when determined by eGFR
and UACR compared with urine protein dipstick testing,
the predictive ability for future cardiovascular events
from UACR-based risk grading was superior to that of
dipstick-based risk grading. Further studies including
cost effectiveness analysis are needed to determine how
best to utilize urine albumin measurement rather than
dipstick testing to reduce the risk for cardiovascular
events in mass screening settings.
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